Rheumatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Universidad Autónoma de Madrid, C/ Diego de León 62, 28006 Madrid, Spain.
Expert Rev Clin Immunol. 2013 Jul;9(7):599-621. doi: 10.1586/1744666X.2013.811192.
Abatacept is approved for the treatment of moderate-to-severe active rheumatoid arthritis (RA) patients with inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs), including methotrexate or a TNF antagonist, and can be used either as monotherapy or concomitantly with nonbiologic DMARDs. It can be administered either intravenously or subcutaneously. It has demonstrated to improve signs and symptoms of RA, physical function and health-related quality of life, and it inhibits radiographic progression of structural damage across a wide range of early and long-standing RA populations. The safety profile appears good and close to RA patients treated with nonbiologic DMARDs. Meta-analysis and real-world studies support these findings. This article reviews published data on clinical and radiographic efficacy as well as the safety of this drug, incorporating recent relevant information reported at scientific meetings.
阿巴西普被批准用于治疗对一种或多种疾病修饰抗风湿药物（DMARDs）治疗反应不足的中重度活跃类风湿关节炎（RA）患者，包括甲氨蝶呤或 TNF 拮抗剂，可单独使用或与非生物 DMARDs 联合使用。它可以静脉注射或皮下注射。它已被证明可以改善 RA 的体征和症状、身体功能和与健康相关的生活质量，并抑制广泛的早期和长期 RA 人群的结构损伤的放射学进展。安全性似乎良好，接近接受非生物 DMARDs 治疗的 RA 患者。荟萃分析和真实世界研究支持这些发现。本文综述了已发表的关于该药物临床和放射学疗效以及安全性的数据，纳入了最近在科学会议上报告的相关信息。
